Mode
Text Size
Log in / Sign up

Heterozygous SERPINA1 genotypes are associated with increased liver disease risks in Alpha-1 Antitrypsin DeficiencySpecific gene variants linked to increased liver disease risks

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize heterozygous SERPINA1 genotypes as a significant risk factor for fibrosis and cirrhosis in Alpha-1 Antitrypsin Deficiency.

The study investigated the relationship between heterozygous SERPINA1 genotypes (MZ and SZ) and various hepatic outcomes in individuals with Alpha-1 Antitrypsin Deficiency. The analysis compared these specific genotypes against control groups to evaluate risks associated with body mass index, steatosis, liver enzymes, and advanced disease progression.

Findings indicated that while BMI and the risk of steatosis were comparable between groups, heterozygotes exhibited modestly higher levels of ALT, AST, and ALP. More notably, the researchers observed significantly increased odds for clinical outcomes including fibrosis, cirrhosis, and the requirement for liver transplantation among those with heterozygous genotypes. These results suggest that these specific genotypes may represent moderate-penetrance liver susceptibility states.

The authors note that while a clear association exists between the genotype and increased disease markers, this study design does not establish causality. Clinicians should view these findings as evidence that heterozygous SERPINA1 genotypes are bona fide risk states for liver pathology. These results may help in identifying high-risk patients who require closer monitoring for progression to advanced liver disease.

Living with a genetic condition like Alpha-1 Antitrypsin Deficiency can be complex. New data helps clarify how specific gene variations, known as heterozygous SERPINA1 genotypes (MZ and SZ), impact liver health. Even in people who carry only one copy of the affected gene, researchers found clear signals of risk.

While these individuals had similar body weights and fat levels compared to others, their liver enzymes—the markers doctors use to check for organ stress—were modestly higher. More importantly, the study showed a significant jump in serious outcomes. People with these specific genotypes had over twice the odds of developing fibrosis (scarring), cirrhosis (severe scarring), and needing a liver transplant.

It is important to remember that while this data shows a strong link between these genes and liver issues, it does not prove that the gene alone causes the disease. These findings help doctors identify specific risk groups who may need closer monitoring for liver health.

What this means for you:
Specific genetic markers are linked to significantly higher risks of liver scarring and transplant needs.

Common questions

How much higher is the risk for those with these specific genes?

The study found that people with these genetic markers had over double the odds of developing fibrosis (odds ratio 2.14) and cirrhosis (odds ratio 2.24). They also faced significantly higher odds of needing a liver transplant, with an odds ratio of 2.28.

Does body weight affect these results?

No, the study found that body mass index (BMI) was comparable between the groups. This means the increased risk for liver issues in people with these specific genetic markers was not linked to their weight or higher fat levels.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
BACKGROUND: Heterozygous SERPINA1 genotypes (MZ, SZ) have historically been regarded as carrier states with limited liver relevance. Emerging evidence suggests increased liver injury, but the magnitude of risk remains uncertain. We synthesized evidence on heterozygous SERPINA1 liver phenotypes to quantify this risk. METHODS: We performed a systematic review of bibliographic databases from inception to 21 October 2025 for studies reporting liver outcomes in MZ or SZ genotypes. Outcomes were grouped into metabolic comorbidities, biochemical markers, and clinical liver disease. Random-effects meta-analyses pooled mean differences (MDs) and odds ratios (ORs); risk of bias was assessed with established tools (PROSPERO CRD420251165586). RESULTS: Twenty-six studies including 27,933 heterozygotes and 547,961 controls met inclusion criteria. BMI (MD -0.09 [-0.20-0.02]) and steatosis risk (OR 1.09 [0.74-1.60]) were comparable between groups. Heterozygotes had modestly higher liver enzymes (ALT MD 1.03 [0.41-1.66]; AST MD 0.68 [0.51-0.85]; ALP MD 2.58 [1.58-3.58]) and higher odds of abnormal ALT (OR 1.18 [1.11-1.25]), AST (OR 1.16 [1.07-1.26]), and ALP (OR 1.41 [1.18-1.68]). They had significantly increased odds of fibrosis (OR 2.14 [1.52-3.02]), cirrhosis (OR 2.24 [1.73-2.91]), and liver transplantation (OR 2.28 [1.45-3.59]). CONCLUSIONS: Heterozygous SERPINA1 genotypes are bona fide liver risk states, with effect sizes comparable to established genetic and environmental determinants. MZ/SZ heterozygosity should be recognized as moderate-penetrance liver susceptibility genotypes in chronic liver disease risk assessment.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.